Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.
children
multidrug-resistant
paediatrics
prevention
rifampicin-resistant
treatment
tuberculosis
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
14
01
2022
revised:
09
02
2022
accepted:
21
02
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Children affected by rifampicin-resistant tuberculosis (RR-TB; TB resistant to at least rifampicin) are a neglected group. Each year an estimated 25,000-30,000 children develop RR-TB disease globally. Improving case detection and treatment initiation is a priority since RR-TB disease is underdiagnosed and undertreated. Untreated paediatric TB has particularly high morbidity and mortality. However, children receiving TB treatment, including for RR-TB, respond well. RR-TB treatment remains a challenge for children, their caregivers and TB programmes, requiring treatment regimens of up to 18 months in duration, often associated with severe and long-term adverse effects. Shorter, safer, effective child-friendly regimens for RR-TB are needed. Preventing progression to disease following
Identifiants
pubmed: 35456056
pii: pathogens11040381
doi: 10.3390/pathogens11040381
pmc: PMC9024964
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29133560
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Eur Respir J. 2021 May 20;57(5):
pubmed: 33243846
Am J Respir Crit Care Med. 2015 Jul 15;192(2):229-37
pubmed: 25915791
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):971-974
pubmed: 33156768
Lancet Glob Health. 2018 Dec;6(12):e1329-e1338
pubmed: 30266570
N Engl J Med. 2019 Mar 28;380(13):1201-1213
pubmed: 30865791
Int J Tuberc Lung Dis. 2021 Sep 1;25(9):716-724
pubmed: 34802493
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
PLoS Med. 2019 Apr 30;16(4):e1002789
pubmed: 31039153
N Engl J Med. 2022 Apr 21;386(16):1490-1493
pubmed: 34986295
Emerg Infect Dis. 2017 Oct;23(10):
pubmed: 28758889
Lancet Infect Dis. 2016 Oct;16(10):1193-1201
pubmed: 27342768
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424
pubmed: 31945300
Clin Infect Dis. 2015 Feb 15;60(4):549-56
pubmed: 25362206
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29463539
Pediatr Radiol. 2004 Nov;34(11):886-94
pubmed: 15300340
Pediatrics. 2006 Nov;118(5):e1350-9
pubmed: 17079536
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30670421
Lancet Glob Health. 2017 Sep;5(9):e898-e906
pubmed: 28807188
Trials. 2018 Dec 20;19(1):693
pubmed: 30572905
BMJ Open. 2020 Jan 2;10(1):e033945
pubmed: 31900274
Clin Infect Dis. 2006 Apr 15;42(8):e69-71
pubmed: 16575719
Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1316-1318
pubmed: 33317680
Int J Tuberc Lung Dis. 2018 May 1;22(5):15-23
pubmed: 29665949
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30803975
Lancet. 2014 May 3;383(9928):1572-9
pubmed: 24671080
Clin Infect Dis. 2017 Jun 15;64(12):1670-1677
pubmed: 28329197
PLoS Med. 2018 Jul 11;15(7):e1002591
pubmed: 29995958
Clin Infect Dis. 2022 Apr 28;74(8):1372-1381
pubmed: 34286843